Academic Perspectives on Systemic Therapy for Advanced uHCC
An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy through imaging, α-fetoprotein levels, and tolerability. Treatment decisions are guided by response assessment, adverse events, and liver function. First-line (1L) options include tyrosine kinase inhibitors and immunotherapy combinations, with promising trials exploring novel immune combinations and targeted approaches that may reshape the treatment landscape.
Video content above is prompted by the following:
- What remaining clinical pearls can you share regarding systemic therapy treatment approaches for patients with advanced uHCC?
- How do you evaluate treatment success over time, and what are key indicators that guide decisions regarding treatment modifications or sequencing?
- What trials are you anticipating that might affect the 1L treatment of uHCC?
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
